Publication | Closed Access

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

OncologyPancreatic CancerGastrointestinal OncologyMetastatic Pancreatic AdenocarcinomaMedicineFixed-dose Rate GemcitabineFirst-line TreatmentPharmacotherapyCancer TreatmentPharmacologyRadiation OncologyCancer Research